Pharma-NHS diabetes project begins
February 9, 2011Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working
A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …
Teva surges ahead
February 9, 2011Sales and Marketing 2010 pharma results, Copaxone, Teva, Teva Pharmaceutical
Generics giant Teva enjoyed a strong year of growth in 2010, lifted by the acquisition of Ratiopharm, patent expiries of …
Dr Matthias joins Noxxon Pharma
February 9, 2011Research and Development Dr Matthias Baumann, Noxxon Pharma, appointment, research and development
Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers. He joins from Focus Clinical Drug Development, …
Melanoma: intense competition to be the next milestone treatment
February 9, 2011Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab
A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …
AZ-Targacept depression candidate moves into phase IIb
February 9, 2011Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder
AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …
Early diagnosis key to UK cancer ambition
February 8, 2011Cancer, NHS, NICE
A series of quality standards on cancer care is to be drawn up by NICE as part of a new …
Genzyme to divest pharma intermediates business
February 8, 2011Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase
Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …
Pharmaceutical facility news in brief
February 8, 2011Manufacturing and Production Baxter International, Famar, Lannett, Qatar Pharma, Sanofi-Aventis, Takeda Pharmaceutical Co
A round-up of news involving manufacturing facilities includes updates from Takeda, Famar/Sanofi, Qatar Pharma, Lannett and Baxter. Takeda Pharmaceutical Co …
Roche eyes ovarian cancer expansion for Avastin
February 8, 2011Sales and Marketing Cancer, Roche, avastin, bevacizumab, ovarian cancer
Roche has submitted an EU marketing authorisation for Avastin for the treatment of ovarian cancer and plans to file the …
Stabilitech appoints new commercial director
February 8, 2011Manufacturing and Production Donna Hackett, Stabilitch, appointment, manufacturing and production
Donna Hackett joins stabilisation company Stabilitch as commercial director. She has 20 years pharma experience, most recently at pre-clinical, clinical …
Teva plant in Israel cited by FDA, expands in Americas
February 8, 2011Manufacturing and Production Corporacion Infarmasa, FDA, Peru, Teva, Teva Pharmaceutical, generics, generics manufacturing, manufacturing compliance
A manufacturing facility in Jerusalem operated by Teva Pharmaceutical failed to pass muster in an FDA inspection, prompting a warning …
Avecia Biotech sold to Nitto Denko
February 8, 2011Manufacturing and Production Avecia, Avecia Biologics, Avecia Biotechnology, Nitto Denko
Avecia Biotechnology, which focuses mainly on the development and manufacturing of oligonuceotide medicines, has been acquired by Japanese firm Nitto …
AZ and Pfizer support personalised medicine database
February 8, 2011Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine
AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …
Merck KGaA appoints Frederic Wohlwend
February 7, 2011Sales and Marketing Frederic Wohlwend, Merck KGaA, appointment, sales and marketing
Frederic Wohlwend has been promoted to chief information officer at Merck KGaA with effect from 1 April. He succeeds Kai …
Pressure mounts on Pfizer and government over UK R&D closure
February 7, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee
The political fallout over Pfizer’s decision to close its Kent R&D base continues apace, with the House of Commons to …
Late-stage blow to AstraZeneca’s prostate cancer drug
February 7, 2011Research and Development AstraZeneca, Cancer, prostate cancer, zibotentan
A late-stage trial of AstraZeneca’s oral prostate cancer drug zibotentan has been halted after it failed to meet its primary …
Survey shows doctors support FDA Avastin decision
February 7, 2011Sales and Marketing FDA, Roche, Sermo, avastin, bevacizumab
A survey of US doctors suggests that a majority support the FDA’s decision to take away Avastin’s licence for use …
GSK profits slump amid ongoing Avandia woes
February 7, 2011Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline
GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …
Merck dipped into the red as 2010 ended
February 4, 2011Sales and Marketing 2010 pharma results, Merck & Co
Merck & Co made a $531 million loss in the final quarter of 2010 – down from a profit of …
Digital Pharma: Merck Serono launches campaign for cancer carers
February 4, 2011Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer
Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
